A Multicenter Study of Anlotinib in Hepatocellular Carcinoma (HCC) Patients at High Risk of Post Surgery Recurrence

Inclusion Criteria: * No allergic history of Anlotinib * 18-75 years * No history of severe arrhythmia or heart failure * No history of severe ventilation dysfunction or severe pulmonary infection * No acute or chronic renal failure, creatinine clearance \> 40 mL/min * Liver function is normal: child-pugh grade A or grade B (≤7 points), total bilirubin ≤ 3.0 mg/dL, albumin ≥ 28 g/L, AST, ALT, ALP≤ 5 times of the upper limit of normal value * Blood test: the absolute neutrophil count ≥ 1.5×10\^9 /L, Hb ≥ 8.5 g/L, PLT ≥ 75×10\^9 /L (without blood transfusions and drug therapy 14 days before the screening) * Blood coagulation function: INR≤2.3 * ECOG: 0-2 * Pathology: hepatocellular carcinoma * Satisfy any of the following: A. portal vein, hepatic vein or bile duct carcinoma thrombus B. microvascular invasion (MVI) grade II (\> 5 MVI, or MVI occurs in the area more than 1 cm from the tumor) C. tumor number ≥ 3 D. preoperative rupture of tumor or tumor invasion adjacent organs * Patients participate in the study voluntarily and sign informed consent Exclusion Criteria: * Pregnant or lactating women * Patients who have had or are currently complicated with other malignant tumors * Recurrent hepatocellular carcinoma * Patients who participated in other clinical trials within 1 month * Patients with mental illness * Patients treated with targeted drugs, immunotherapy (such as PD1 antibody), FOLFOX systemic chemotherapy or huaier granules after surgery * Urine protein ≥ ++，and 24-hour urinary protein excretion\>1.0 g confirmed